Web Exclusives

Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future.

A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey.

COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals.

Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas.

Sharing your cancer story can promote your sense of what’s truly important, giving you hope and strength in difficult times.

Jim Palma and John Hopper, Co-Chairs of NORD Rare Cancer Coalition, explain the difference between genetic testing and genomic profile testing, and why all patients with rare cancers should have a genomic profile done to select the best treatment for them based on potential genomic alteration.

The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib.

A recent study provides some of the first data on COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia.